<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00442780</url>
  </required_header>
  <id_info>
    <org_study_id>204PD203</org_study_id>
    <secondary_id>EUDRA CT NO: 2007-000398-47</secondary_id>
    <nct_id>NCT00442780</nct_id>
  </id_info>
  <brief_title>Dose-Finding Safety Study of BIIB014 in Early-Stage Parkinson's Disease</brief_title>
  <acronym>MOBILE</acronym>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Dose Escalation Study of Multiple Doses of BIIB014 Administered Orally in Subjects With Early Parkinson's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine the safety of BIIB014 and how well BIIB014 is&#xD;
      tolerated when given at different doses to patients with early-stage Parkinson's Disease.&#xD;
&#xD;
      This study will also explore:&#xD;
&#xD;
        -  How BIIB014 is affected when given to patients with early-stage Parkinson's Disease&#xD;
           (this will be done by measuring the levels of BIIB014 in the blood at several different&#xD;
           times during the study), and&#xD;
&#xD;
        -  The activity of BIIB014 when given to early Parkinson's patients (this will be done by&#xD;
           performing different Parkinson's Disease assessments and other tests during the study).&#xD;
&#xD;
      Patients who enter this study will be randomly assigned to receive either BIIB014 or a&#xD;
      placebo but because the study is blinded, neither they nor their study doctor will know which&#xD;
      study treatment they are taking.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number and proportion of subjects with adverse events</measure>
    <time_frame>up to end of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of clinical laboratory parameters.</measure>
    <time_frame>up to end of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of vital signs.</measure>
    <time_frame>up to end of study</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of ECG parameters.</measure>
    <time_frame>up to end of study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess PK by measuring concentrations of BIIB014 and its N-acetyl metabolite in blood plasma.</measure>
    <time_frame>up to end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Explore BIIB014 activity by evaluating standard Parkinson's disease assessments.</measure>
    <time_frame>up to end of study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Explore the PK/pharmacodynamic relationships for BIIB014.</measure>
    <time_frame>up to end of study</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Parkinson's Disease</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose Level A of BIIB014</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose Level B of BIIB014</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose Level C of BIIB014</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Dose Level D of BIIB014</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIIB014</intervention_name>
    <description>oral administration of BIIB014 per dose, schedule,and duration specified in protocol</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration of placebo matched to BIIB014 dose level; placebo to follow same dosing schedule as BIIB014</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Must give written informed consent and any authorizations required by local law.&#xD;
&#xD;
          -  Must carry a diagnosis of idiopathic Parkinson's Disease(PD), without any other known&#xD;
             or suspected cause of parkinsonism, according to the UK Parkinson's Disease Society&#xD;
             Brain Bank Clinical Diagnostic Criteria. Initial diagnosis of PD must have been made&#xD;
             within the 5 years prior to Screening with at least two or more of the following&#xD;
             cardinal signs being present: bradykinesia, resting tremor, rigidity, and postural&#xD;
             instability.&#xD;
&#xD;
          -  Must be modified Hoehn &amp; Yahr Stage 1 to 2.5 (inclusive).&#xD;
&#xD;
          -  Must have a baseline UPDRS (Part III) motor score of at least 10.&#xD;
&#xD;
          -  Subjects may be receiving an anticholinergic agent and/or MAO-B inhibitor (if they&#xD;
             have been on a stable dose of that medication for at least 4 weeks prior to study&#xD;
             entry) but must not be receiving any other PD medication.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A Mini Mental State Examination (MMSE) score &lt;26.&#xD;
&#xD;
          -  History or clinical features consistent with an atypical parkinsonian syndrome.&#xD;
&#xD;
          -  Any significant non-PD central nervous system disorder.&#xD;
&#xD;
          -  Any significant AXIS I psychiatric disease as defined by the Diagnostic and&#xD;
             Statistical Manual of Mental Disorders.&#xD;
&#xD;
          -  History of cognitive or neuropsychiatric conditions.&#xD;
&#xD;
          -  History of surgical intervention for PD.&#xD;
&#xD;
          -  History of L-DOPA-induced motor or non-motor complication.&#xD;
&#xD;
          -  History of malignancy.&#xD;
&#xD;
          -  History of severe allergic or anaphylactic reactions to any drug.&#xD;
&#xD;
          -  Clinically significant renal dysfunction.&#xD;
&#xD;
          -  HbA1c &gt;7.0%.&#xD;
&#xD;
          -  Clinically significant baseline ECG.&#xD;
&#xD;
          -  Orthostatic hypotension.&#xD;
&#xD;
          -  Treatment with L-DOPA/carbidopa or L-DOPA/benserazide for more than 6 cumulative&#xD;
             months at anytime since subject's initial PD diagnosis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Biogen Idec, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cambridge, MA USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ashkelon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Petach Tikva</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ramat-Gan</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kielce</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Sites</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Belgrade</city>
        <country>Serbia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>Poland</country>
    <country>Serbia</country>
  </location_countries>
  <removed_countries>
    <country>Former Serbia and Montenegro</country>
  </removed_countries>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>March 1, 2007</study_first_submitted>
  <study_first_submitted_qc>March 1, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2007</study_first_posted>
  <last_update_submitted>January 8, 2009</last_update_submitted>
  <last_update_submitted_qc>January 8, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 9, 2009</last_update_posted>
  <responsible_party>
    <name_title>Biogen Idec MD</name_title>
    <organization>Biogen Idec</organization>
  </responsible_party>
  <keyword>early Parkinson's Disease</keyword>
  <keyword>MOBILE</keyword>
  <keyword>BIIB014</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>3-(4-amino-3-methylbenzyl)-7-(2-furyl)-3H-(1,2,3)triazolo(4,5-d)pyrimidine-5-amine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

